The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting
The Australasian Psoriasis Collaboration reviewed methotrexate (MTX) in the management of psoriasis in the Australian and New Zealand setting. The following comments are based on expert opinion and a literature review. Low-dose MTX (< 0.4 mg/kg per week) has a slow onset of action and has moderate to good efficacy, together with an acceptable safety profile. The mechanism of action is anti-inflammatory, rather than immunosuppressive. For pretreatment, consider testing full blood count (FBC),...[Show more]
|Collections||ANU Research Publications|
|Source:||Australasian Journal of Dermatology|
|210923-dermo.pdf||Published version||61.93 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.